Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

Antzeko izenburuak

• Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
  nork: Philip Helliwell, et al.
  Argitaratua: (2018-10-01)
• Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
  nork: Helliwell, P, et al.
  Argitaratua: (2018)
• Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
  nork: Nash, P, et al.
  Argitaratua: (2018)
• Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study
  nork: Nash, P, et al.
  Argitaratua: (2018)
• Janus kinase inhibitors in the treatment of psoriatic arthritis
  nork: E. Yu. Loginova, et al.
  Argitaratua: (2022-02-01)